OVCAS1
MCID: OVR114
MIFTS: 59

Ovarian Cancer 1 (OVCAS1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 57 29
Ovarian Cancer, Susceptibility to, 1 57 13
Ovarian Cancer, Susceptibility to 57 6
Malignant Neoplasm of Ovary 71
Epithelial Ovarian Cancer 71
Ovarian Carcinoma 71
Ovarian Cancer 57
Ovcas1 57

Classifications:



External Ids:

OMIM® 57 607893
UMLS 71 C0029925 C0677886 C1140680

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian cancer, susceptibility to, 1, is related to breast-ovarian cancer, familial 2 and familial ovarian cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are DNA Double-Strand Break Repair and DNA Damage. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and breast, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

More information from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 950)
# Related Disease Score Top Affiliating Genes
1 breast-ovarian cancer, familial 2 32.8 BRCA2 BRCA1
2 familial ovarian cancer 32.0 BRCA2 BRCA1
3 hereditary site-specific ovarian cancer syndrome 31.6 RAD51C BRCA2 BRCA1
4 fallopian tube carcinoma 31.1 RAD51C PALB2 BRCA2 BRCA1
5 hereditary breast ovarian cancer syndrome 31.1 RAD51C PALB2 NBN LOC111589216 BRCA2 BRCA1
6 primary peritoneal carcinoma 31.1 BRCA2 BRCA1
7 hereditary nonpolyposis colon cancer 30.8 BRCA2 BRCA1
8 ovarian cystadenocarcinoma 30.7 BRCA2 BRCA1
9 lynch syndrome 30.7 RAD51C PALB2 NBN BRCA2 BRCA1
10 papillary serous adenocarcinoma 30.6 BRCA2 BRCA1
11 dysgerminoma 30.4 BRCA2 BRCA1
12 papillary adenocarcinoma 30.4 BRCA2 BRCA1
13 bilateral breast cancer 30.3 PALB2 BRCA2 BRCA1
14 ataxia-telangiectasia 30.3 NBN BRCA2 BRCA1
15 breast-ovarian cancer, familial 1 30.2 RAD51C PALB2 NBN LOC111589216 BRCA2 BRCA1
16 female breast cancer 30.2 PALB2 BRCA2 BRCA1
17 tetraploidy 30.1 BRCA2 BRCA1
18 endosalpingiosis 30.1 BRCA2 BRCA1
19 female reproductive endometrioid cancer 30.0 BRCA2 BRCA1
20 uterine corpus cancer 30.0 BRCA2 BRCA1
21 hypertrophy of breast 29.9 BRCA2 BRCA1
22 premature menopause 29.9 RAD51C NBN BRCA2 BRCA1
23 li-fraumeni syndrome 29.8 RAD51C PALB2 BRCA2 BRCA1
24 fanconi anemia, complementation group n 29.7 RAD51C PALB2 BRCA2
25 fanconi anemia, complementation group a 29.6 RAD51C PALB2 NBN BRCA2 BRCA1
26 lobular neoplasia 29.6 BRCA2 BRCA1
27 bap1 tumor predisposition syndrome 29.5 PALB2 BRCA2
28 fanconi anemia, complementation group q 29.5 RAD51C PALB2
29 fanconi anemia, complementation group p 29.5 RAD51C PALB2
30 sporadic breast cancer 29.4 RAD51C PALB2 NBN BRCA2 BRCA1
31 peritoneum cancer 29.4 RAD51C PALB2 BRCA2 BRCA1
32 fanconi anemia, complementation group j 29.3 RAD51C PALB2 BRCA2 BRCA1
33 cerebellar disease 29.3 NBN BRCA2 BRCA1
34 cowden syndrome 29.2 RAD51C PALB2 BRCA2 BRCA1
35 islet cell tumor 29.0 PALB2 BRCA2
36 fallopian tube disease 29.0 RAD51C PALB2 BRCA2 BRCA1
37 gastric cancer, hereditary diffuse 28.8 RAD51C PALB2 NBN BRCA2 BRCA1
38 ovarian cancer 27.3 RAD51C PHF13 PALB2 OVCAS1 NBN FILIP1L
39 ovarian epithelial cancer 11.8
40 breast-ovarian cancer, familial 3 11.6
41 breast-ovarian cancer, familial 4 11.5
42 pancreatic cancer 11.2
43 paraneoplastic cerebellar degeneration 11.1
44 ovarian small cell carcinoma 11.1
45 ovarian disease 11.1
46 neutropenia 11.1
47 breast cancer 11.1
48 ovarian germ cell cancer 11.0
49 endometriosis 11.0
50 ovarian melanoma 11.0

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM®:

607893 (Updated 05-Mar-2021)

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 9.9 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 9.9 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 9.9 BRCA1 BRCA2 PALB2
4 Decreased homologous recombination repair frequency GR00236-A-2 9.9 BRCA1 BRCA2 PALB2
5 Decreased homologous recombination repair frequency GR00236-A-3 9.9 BRCA1 BRCA2 PALB2
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BRCA1 BRCA2 NBN PALB2
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BRCA1 BRCA2 PALB2
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.36 BRCA1 BRCA2 NBN RAD51C
9 Synthetic lethal with cisplatin GR00101-A-1 8.96 BRCA1 BRCA2

MGI Mouse Phenotypes related to Ovarian Cancer 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.43 BRCA1 BRCA2 DPH1 NBN PALB2 RAD51C
2 neoplasm MP:0002006 9.02 BRCA1 BRCA2 DPH1 NBN PALB2

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 478)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
3
Tranexamic Acid Approved Phase 4 1197-18-8 5526
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Iron Approved Phase 4 7439-89-6 23925 29936
6
Ferrous fumarate Approved Phase 4 141-01-5
7
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
8 glucocorticoids Phase 4
9 Antiemetics Phase 4
10 Fibrinolytic Agents Phase 4
11 Platelet Aggregation Inhibitors Phase 4
12 Antipyretics Phase 4
13
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
14
Hydralazine Approved Phase 3 86-54-4 3637
15
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
16
Nintedanib Approved Phase 3 656247-17-5 56843413
17
Epirubicin Approved Phase 3 56420-45-2 41867
18
Melphalan Approved Phase 3 148-82-3 4053 460612
19
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
20
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
21
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
22
Busulfan Approved, Investigational Phase 3 55-98-1 2478
23
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
24
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
25
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
26
tannic acid Approved Phase 3 1401-55-4
27
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
28
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
29
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
30
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
31
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
32
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
33
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
34
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
35
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
36
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
37
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
38
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
39
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
40
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
41
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
42
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
43
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
44
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
45
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
46
carbamide peroxide Approved Phase 3 124-43-6
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
48 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
49
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
50
Farletuzumab Investigational Phase 3 896723-44-7

Interventional clinical trials:

(show top 50) (show all 1636)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
3 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
4 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
5 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
6 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
7 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
9 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
10 Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer Recruiting NCT03164980 Phase 4 Trabectidin (Yondelis)
11 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
12 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
13 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
14 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
15 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
16 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Recruiting NCT04352439 Phase 4 Aspirin
17 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
18 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
19 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
20 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
21 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
22 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
23 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study Unknown status NCT02681432 Phase 3 HIPEC
24 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
25 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
26 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
27 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
28 Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT. Unknown status NCT03162276 Phase 3
29 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
30 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
31 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
32 A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Unknown status NCT01837251 Phase 3 Carboplatin;PLD
33 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
34 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
35 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
36 Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers Unknown status NCT03717610 Phase 3
37 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
38 Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line Completed NCT02490488 Phase 2, Phase 3 Masitinib;Gemcitabine;Placebo
39 Impact of Exercise on Ovarian Cancer Prognosis Completed NCT02107066 Phase 3
40 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
41 A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
42 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
43 Randomized Trial of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Completed NCT01091636 Phase 2, Phase 3
44 FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Completed NCT02631876 Phase 3 Mirvetuximab soravtansine;Paclitaxel;Pegylated liposomal doxorubicin;Topotecan
45 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Completed NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
46 An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) Completed NCT00989131 Phase 3 Paclical®;Taxol®
47 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
48 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
49 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
50 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin

Search NIH Clinical Center for Ovarian Cancer 1

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 29

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

40
Ovary, T Cells, Breast, Prostate, Bone, Lymph Node, Colon

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 145)
# Title Authors PMID Year
1
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1. 6
29712865 2018
2
Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients. 6
29133208 2018
3
Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. 6
25472942 2015
4
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. 6
23269703 2013
5
BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. 6
22425665 2012
6
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. 6
21946536 2011
7
A novel BRCA1 mutation in a Spanish patient with ovarian cancer. 6
18278587 2009
8
Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes. 6
18940477 2008
9
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. 6
18762988 2008
10
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. 6
18285836 2008
11
Nijmegen breakage syndrome (NBS) due to maternal isodisomy of chromosome 8. 6
17103455 2007
12
The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. 6
16941470 2006
13
ATM activation by ionizing radiation requires BRCA1-associated BAAT1. 6
16452482 2006
14
Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability. 6
16033915 2006
15
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. 6
15712267 2005
16
Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. 6
15383404 2004
17
BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. 6
15024741 2004
18
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. 6
12955716 2003
19
657del5 mutation in the gene for Nijmegen breakage syndrome (NBS1) in a cohort of Russian children with lymphoid tissue malignancies and controls. 6
12833396 2003
20
Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic. 6
12566964 2003
21
Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. 6
12427738 2003
22
Frequency of 657del(5) mutation of the NBS1 gene in the Czech population by polymerase chain reaction with sequence specific primers. 6
12505263 2002
23
Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins. 6
12220453 2002
24
657del5 mutation in the NBS1 gene is associated with Nijmegen breakage syndrome in a Turkish family. 6
12123493 2002
25
Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula. 6
12014998 2002
26
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. 6
11748848 2001
27
The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. 6
11781691 2001
28
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. 6
11385711 2001
29
Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. 57
11440995 2001
30
An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. 6
11279524 2001
31
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. 6
11157798 2001
32
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. 6
11039575 2000
33
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. 6
10827109 2000
34
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. 6
10788334 2000
35
Clinical presentation and mutation identification in the NBS1 gene in a boy with Nijmegen breakage syndrome. 6
10852373 2000
36
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. 6
10441573 1999
37
De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. 6
10417300 1999
38
Evidence for a BRCA1 founder mutation in families of West African ancestry. 6
10417303 1999
39
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. 6
10398434 1999
40
Germline BRCA1 alterations in a population-based series of ovarian cancer cases. 6
10196379 1999
41
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. 6
9764635 1998
42
A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. 6
9585617 1998
43
Positional cloning of the gene for Nijmegen breakage syndrome. 6
9620777 1998
44
Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. 6
9625172 1998
45
Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. 6
9590180 1998
46
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. 6
9536083 1998
47
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. 6
9616287 1997
48
Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? 6
9450187 1997
49
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. 6
9354803 1997
50
Protease inhibitor-associated hyperglycaemia. 6
9291911 1997

Variations for Ovarian Cancer 1

ClinVar genetic disease variations for Ovarian Cancer 1:

6 (show top 50) (show all 8282)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BRCA1 NM_007294.4(BRCA1):c.190T>G (p.Cys64Gly) SNV Pathogenic 17660 rs80357064 17:41258495-41258495 17:43106478-43106478
2 BRCA1 NM_007294.4(BRCA1):c.181T>G (p.Cys61Gly) SNV Pathogenic 17661 rs28897672 17:41258504-41258504 17:43106487-43106487
3 BRCA1 NM_007294.4(BRCA1):c.66_67AG[1] (p.Glu23fs) Microsatellite Pathogenic 17662 rs80357914 17:41276045-41276046 17:43124028-43124029
4 BRCA1 NM_007294.4(BRCA1):c.1175_1214del (p.Leu392fs) Deletion Pathogenic 17665 rs80359874 17:41246334-41246373 17:43094317-43094356
5 BRCA1 NM_007294.4(BRCA1):c.2292_2293AG[2] (p.Glu765_Ser766insTer) Microsatellite Pathogenic 17666 rs80357780 17:41245251-41245252 17:43093234-43093235
6 BRCA1 NM_007294.4(BRCA1):c.2681_2682del (p.Lys894fs) Deletion Pathogenic 17667 rs80357971 17:41244866-41244867 17:43092849-43092850
7 BRCA1 NM_007294.3(BRCA1):c.3005delA (p.Asn1002Thrfs) Deletion Pathogenic 17669 rs80357601 17:41244543-41244543 17:43092526-43092526
8 PALB2 NM_024675.4(PALB2):c.1535dup (p.Tyr512Ter) Duplication Pathogenic 870643 16:23646331-23646332 16:23635010-23635011
9 RAD51C NM_058216.3(RAD51C):c.104dup (p.Ala35_Glu36insTer) Duplication Pathogenic 870644 17:56770107-56770108 17:58692746-58692747
10 BRCA1 NM_007294.4(BRCA1):c.3607C>T (p.Arg1203Ter) SNV Pathogenic 17671 rs62625308 17:41243941-41243941 17:43091924-43091924
11 BRCA1 NM_007294.4(BRCA1):c.3748G>T (p.Glu1250Ter) SNV Pathogenic 17672 rs28897686 17:41243800-41243800 17:43091783-43091783
12 BRCA1 NM_007294.4(BRCA1):c.3752_3755GTCT[1] (p.Ser1253fs) Microsatellite Pathogenic 17673 rs80357868 17:41243789-41243792 17:43091772-43091775
13 BRCA1 NM_007294.4(BRCA1):c.4065_4068del (p.Asn1355fs) Deletion Pathogenic 17674 rs80357508 17:41243480-41243483 17:43091463-43091466
14 BRCA1 NM_007294.4(BRCA1):c.4327C>T (p.Arg1443Ter) SNV Pathogenic 17675 rs41293455 17:41234451-41234451 17:43082434-43082434
15 BRCA1 NM_007294.4(BRCA1):c.2389G>T (p.Glu797Ter) SNV Pathogenic 17682 rs62625306 17:41245159-41245159 17:43093142-43093142
16 BRCA1 NM_007294.4(BRCA1):c.843_846del (p.Ser282fs) Deletion Pathogenic 17683 rs80357919 17:41246702-41246705 17:43094685-43094688
17 BRCA1 NM_007294.4(BRCA1):c.3481_3491del (p.Glu1161fs) Deletion Pathogenic 17684 rs80357877 17:41244057-41244067 17:43092040-43092050
18 BRCA1 NM_007294.4(BRCA1):c.1556del (p.Lys519fs) Deletion Pathogenic 17685 rs80357662 17:41245992-41245992 17:43093975-43093975
19 BRCA1 NM_007294.4(BRCA1):c.815_824dup (p.Thr276fs) Duplication Pathogenic 55723 rs387906563 17:41246723-41246724 17:43094706-43094707
20 BRCA1 BRCA1, 6-KB DUP, EX13 Insertion Pathogenic 17690
21 BRCA1 NM_007294.3(BRCA1):c.3048_3052dupTGAGA (p.Asn1018Metfs) Duplication Pathogenic 54763 rs80357856 17:41244495-41244496 17:43092478-43092479
22 BRCA1 NM_007294.4(BRCA1):c.211A>G (p.Arg71Gly) SNV Pathogenic 17693 rs80357382 17:41258474-41258474 17:43106457-43106457
23 BRCA1 NM_007294.4(BRCA1):c.5324T>G (p.Met1775Arg) SNV Pathogenic 17694 rs41293463 17:41203088-41203088 17:43051071-43051071
24 BRCA1 NM_007294.4(BRCA1):c.5324T>A (p.Met1775Lys) SNV Pathogenic 17695 rs41293463 17:41203088-41203088 17:43051071-43051071
25 BRCA1 NM_007294.4(BRCA1):c.1016del (p.Lys339fs) Deletion Pathogenic 37386 rs80357569 17:41246532-41246532 17:43094515-43094515
26 BRCA1 NM_007294.4(BRCA1):c.1018del (p.Lys339_Val340insTer) Deletion Pathogenic 37387 rs80357774 17:41246530-41246530 17:43094513-43094513
27 BRCA1 NM_007294.4(BRCA1):c.1121del (p.Thr374fs) Deletion Pathogenic 37391 rs80357612 17:41246427-41246427 17:43094410-43094410
28 BRCA1 NM_007294.4(BRCA1):c.116G>A (p.Cys39Tyr) SNV Pathogenic 37392 rs80357498 17:41267761-41267761 17:43115744-43115744
29 BRCA1 NM_007294.4(BRCA1):c.116G>T (p.Cys39Phe) SNV Pathogenic 37393 rs80357498 17:41267761-41267761 17:43115744-43115744
30 BRCA1 NM_007294.4(BRCA1):c.1175_1215del (p.Leu392fs) Deletion Pathogenic 37394 rs397507180 17:41246333-41246373 17:43094316-43094356
31 BRCA1 NM_007294.4(BRCA1):c.1175_1216del (p.Leu392_Asn406delinsHis) Deletion Pathogenic 37395 rs397507181 17:41246332-41246373 17:43094315-43094356
32 BRCA1 NM_007294.4(BRCA1):c.1177_1219del (p.Leu393fs) Deletion Pathogenic 37396 rs397507182 17:41246329-41246371 17:43094312-43094354
33 BRCA1 NM_007294.4(BRCA1):c.1175_1218del (p.Leu392fs) Deletion Pathogenic 37397 rs397507183 17:41246330-41246373 17:43094313-43094356
34 BRCA1 NM_007294.3(BRCA1):c.5266dupC (p.Gln1756Profs) Duplication Pathogenic 17677 rs80357906 17:41209079-41209080 17:43057062-43057063
35 BRCA1 NM_007294.4(BRCA1):c.4966_4984del (p.Gly1656fs) Deletion Pathogenic 17679 rs80359884 17:41222947-41222965 17:43070930-43070948
36 BRCA1 NM_007294.4(BRCA1):c.1356_1357AG[2] (p.Glu453_Ser454insTer) Microsatellite Pathogenic 37406 rs80357969 17:41246187-41246188 17:43094170-43094171
37 BRCA1 NM_007294.4(BRCA1):c.1380dup (p.Phe461fs) Duplication Pathogenic 54226 rs80357714 17:41246167-41246168 17:43094150-43094151
38 BRCA1 NM_007294.3(BRCA1):c.1387_1390delAAAAins5 Indel Pathogenic 37408 17:41246158-41246161 17:43094141-43094144
39 BRCA1 NM_007294.4(BRCA1):c.1389_1390delinsG (p.Thr464fs) Indel Pathogenic 37409 rs273897659 17:41246158-41246159 17:43094141-43094142
40 BRCA1 NM_007294.4(BRCA1):c.135-1G>T SNV Pathogenic 37404 rs80358158 17:41258551-41258551 17:43106534-43106534
41 BRCA1 NM_007294.4(BRCA1):c.143del (p.Met48fs) Deletion Pathogenic 37412 rs80357637 17:41258542-41258542 17:43106525-43106525
42 BRCA1 NM_007294.4(BRCA1):c.1444_1447del (p.Leu481_Ile482insTer) Deletion Pathogenic 37413 rs80357801 17:41246101-41246104 17:43094084-43094087
43 BRCA1 NM_007294.4(BRCA1):c.1480C>T (p.Gln494Ter) SNV Pathogenic 37415 rs80357010 17:41246068-41246068 17:43094051-43094051
44 BRCA1 NM_007294.4(BRCA1):c.1504_1508del (p.Leu502fs) Deletion Pathogenic 37417 rs80357888 17:41246040-41246044 17:43094023-43094027
45 BRCA1 NM_007294.4(BRCA1):c.1510del (p.Arg504fs) Deletion Pathogenic 37418 rs80357908 17:41246038-41246038 17:43094021-43094021
46 BRCA1 NM_007294.4(BRCA1):c.1674del (p.Gly559fs) Deletion Pathogenic 37425 rs80357600 17:41245874-41245874 17:43093857-43093857
47 BRCA1 NM_007294.4(BRCA1):c.1687C>T (p.Gln563Ter) SNV Pathogenic 37426 rs80356898 17:41245861-41245861 17:43093844-43093844
48 BRCA1 NM_007294.4(BRCA1):c.1921dup (p.Ile641fs) Duplication Pathogenic 37434 rs397507194 17:41245626-41245627 17:43093609-43093610
49 BRCA1 NM_007294.3(BRCA1):c.1953_1956delGAAA (p.Lys653Serfs) Deletion Pathogenic 37435 rs80357526 17:41245592-41245595 17:43093575-43093578
50 BRCA1 NM_007294.4(BRCA1):c.1960A>T (p.Lys654Ter) SNV Pathogenic 37436 rs80357355 17:41245588-41245588 17:43093571-43093571

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

Pathways related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 RAD51C PALB2 NBN BRCA2 BRCA1
2 12.12 NBN BRCA2 BRCA1
3
Show member pathways
12.02 RAD51C NBN BRCA2 BRCA1
4
Show member pathways
11.65 RAD51C PALB2 NBN BRCA2 BRCA1
5 11.43 RAD51C PALB2 BRCA2 BRCA1
6
Show member pathways
11.42 NBN BRCA2 BRCA1
7
Show member pathways
11.2 RAD51C PALB2 NBN BRCA2 BRCA1
8 11.1 NBN BRCA1
9 10.9 NBN BRCA1
10 10.78 NBN BRCA1

GO Terms for Ovarian Cancer 1

Cellular components related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.46 RAD51C NBN BRCA2 BRCA1
2 replication fork GO:0005657 8.96 RAD51C NBN
3 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.83 PHF13 NBN BRCA2 BRCA1
2 cell proliferation GO:0008283 9.67 NBN DPH1 BRCA2
3 cellular response to DNA damage stimulus GO:0006974 9.65 RAD51C PALB2 NBN BRCA2 BRCA1
4 DNA repair GO:0006281 9.55 RAD51C PALB2 NBN BRCA2 BRCA1
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 BRCA2 BRCA1
6 double-strand break repair GO:0006302 9.54 NBN BRCA2 BRCA1
7 male meiosis I GO:0007141 9.51 RAD51C BRCA2
8 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 BRCA2 BRCA1
9 DNA double-strand break processing GO:0000729 9.46 NBN BRCA1
10 inner cell mass cell proliferation GO:0001833 9.43 PALB2 BRCA2
11 telomere maintenance via recombination GO:0000722 9.4 RAD51C BRCA2
12 chordate embryonic development GO:0043009 9.32 BRCA2 BRCA1
13 DNA recombination GO:0006310 9.26 RAD51C PALB2 BRCA2 BRCA1
14 double-strand break repair via homologous recombination GO:0000724 9.02 RAD51C PALB2 NBN BRCA2 BRCA1

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....